A One-Year, Randomized, Double-Blind, Placebo-Controlled Trial of Rosiglitazone in Non-Alcoholic Steatohepatitis

Overview

This study is intended to find out whether treatment with rosiglitazone improves the state of the liver and related blood markers in patients with nonalcoholic steatohepatitis (NASH).

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double

Detailed Description

Phase one : A double blind randomized placebo controlled trial of rosiglitazone – 64 pts with biopsy proven NASH will be randomized to receive either rosiglitazone 8 mg/day or placebo for one year. – after one year of treatment patients will undergo a liver biopsy then a 4 month follow off treatment Primary endpoint: improvement of at least 30% of the histological score of steatosis Secondary endpoints: improvement in ALT values, in necrosis and inflammation and fibrosis Phase II extension open label trial All participants to the phase one regardless of the drug received in the first year will be treated with rosiglitazone for 2 additional years. A liver biopsy will be performed at the end of these two additional years in order to find out whether prolonged rosiglitazone therapy further results in improvement of liver injury in NASH patients.

Interventions

  • Drug: rosiglitazone

Clinical Trial Outcome Measures

Primary Measures

  • improvement in steatosis

Secondary Measures

  • improvement in transaminase levels; improvement/less worsening in necrosis and inflammatory activity and /or fibrosis

Participating in This Clinical Trial

Inclusion Criteria

  • Histologically proven NASH with steatosis >= 20% – Increased serum ALT Exclusion Criteria:

  • bland steatosis – daily alcohol > 20/30 g (women/men) – any other cause of liver disease – secondary NASH including drug-induced steatohepatitis – treatment with insulin or glitazones – cardiac insufficiency – Hb < 10 g/dl

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Association pour la Recherche sur les Maladies Hépatiques Virales
  • Overall Official(s)
    • Vlad Ratziu, MD PhD, Principal Investigator, Hôpital Pitié Salpêtrière, APHP

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.